From Wikipedia, the free encyclopedia
Chemical compound
Icenticaftor
![](https://upload.wikimedia.org/wikipedia/commons/thumb/3/3a/Icenticaftor.svg/220px-Icenticaftor.svg.png) |
|
Other names | QBW251 |
---|
ATC code | |
---|
|
3-Amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)pyridine-2-carboxamide
|
CAS Number | |
---|
PubChem
CID | |
---|
ChemSpider | |
---|
UNII | |
---|
KEGG | |
---|
CompTox Dashboard (
EPA) | |
---|
|
Formula | C12H13F6N3O3 |
---|
Molar mass | 361.244 g·mol−1 |
---|
3D model (
JSmol) | |
---|
C[C@](CNC(=O)C1=C(C=C(C(=N1)OC)C(F)(F)F)N)(C(F)(F)F)O
|
InChI=1S/C12H13F6N3O3/c1-10(23,12(16,17)18)4-20-8(22)7-6(19)3-5(11(13,14)15)9(21-7)24-2/h3,23H,4,19H2,1-2H3,(H,20,22)/t10-/m0/s1 Key:USHQRIKZLHNPQR-JTQLQIEISA-N
|
Icenticaftor (development code QBW251) is a drug candidate for the treatment of
chronic obstructive pulmonary disease (COPD)
[1]
[2] and
cystic fibrosis.
[3]
[4] The drug is being
developed by
Novartis.
[5]
Like
ivacaftor (which is marketed as Kalydeco), icenticaftor functions by acting as a stimulator of the protein
cystic fibrosis transmembrane conductance regulator (CFTR).
[5]
References
-
^ Rowe SM, Jones I, Dransfield MT, Haque N, Gleason S, Hayes KA, et al. (2020).
"Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial". International Journal of Chronic Obstructive Pulmonary Disease. 15: 2399–2409.
doi:
10.2147/COPD.S257474.
PMC
7547289.
PMID
33116455.
-
^ Grand DL, Gosling M, Baettig U, Bahra P, Bala K, Brocklehurst C, et al. (June 2021).
"Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease". Journal of Medicinal Chemistry. 64 (11): 7241–7260.
doi:
10.1021/acs.jmedchem.1c00343.
ISSN
0022-2623.
PMID
34028270.
-
^ Kazani S, Rowlands DJ, Bottoli I, Milojevic J, Alcantara J, Jones I, et al. (March 2021).
"Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)". Journal of Cystic Fibrosis. 20 (2): 250–256.
doi:
10.1016/j.jcf.2020.11.002.
PMC
8935475.
PMID
33293212.
-
^ Ray F (December 9, 2020).
"Icenticaftor Effective in CF Patients With Certain Mutations, Phase 1/2 Trial Shows". cysticfibrosisnewstoday.com. BioNews Services.
- ^
a
b
"Icenticaftor – Novartis". Adis Insight. Springer Nature Switzerland AG.